var data={"title":"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6048?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161261\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adacel;</li>\n      <li>Boostrix;</li>\n      <li>Daptacel;</li>\n      <li>Infanrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161262\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adacel;</li>\n      <li>Boostrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161272\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161265\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tdap can be administered regardless of the interval between the last tetanus or diphtheria toxoid containing vaccine. Tdap is currently recommended for a single dose only (CDC/ACIP 60[1] 2011; CDC/ACIP 61[25] 2012), except pregnant females who should receive a Tdap dose during each pregnancy (preferably during the early part of 27 and 36 weeks&rsquo; gestation) (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization: ACIP recommendations:</b> IM: Adults &ge;19 years: 0.5 mL per dose. A single dose of Tdap should be given to replace a single dose of the 10 year Td booster in patients who have not previously received Tdap or for whom vaccine status is not known. A single dose of Tdap is recommended for health care personnel who have not previously received Tdap and who have direct patient contact (CDC [Kretsinger 2006]). Tdap should be administered regardless of interval since last tetanus- or diphtheria-containing vaccine (CDC/ACIP 61[25] 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization: Manufacturer's labeling:</b> IM: Adults (Adacel [&le;64 years], Boostrix): 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Wound management (CDC/ACIP [Broder 2006]):</b> IM: Adacel or Boostrix may be used as an alternative to Td vaccine when a tetanus toxoid-containing vaccine is needed for wound management, and in whom the pertussis component is also indicated. Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated, the immunization status of the patient. Wound management includes proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Tetanus Prophylaxis in Wound Management</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">History of Tetanus Immunization Doses</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Clean, Minor Wounds</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">All Other Wounds<sup>1</sup></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus Toxoid<sup>2</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus Toxoid<sup>2</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Tetanus toxoid in this chart refers to a tetanus toxoid-containing vaccine. For children &le;6 years of age, DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years, adolescents, and adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Yes, if &ge;10 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Yes, if &ge;5 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"top\" align=\"left\">\n            <p style=\"text-indent:0em;\">Abbreviations: <b>DT</b> = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years); <b>DTaP</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;); <b>Td</b> = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac&reg;,Tenivac&trade;); <b>TT</b>= Tetanus toxoid (adsorbed [formulation for age &ge;7 years]); <b>Tdap</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]); <b>TIG</b> = Tetanus Immune Globulin</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Uncertain or &lt;3 doses</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>3 or more doses</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161268\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 weeks to &lt;7 years: <b>Note:</b> Whenever possible, the same product should be used for all doses. Interruption of recommended schedule does not require starting the series over; a delay between doses should not interfere with final immunity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Daptacel, Infanrix: 0.5 mL per dose, total of 5 doses administered as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Three doses, usually given at 2-, 4-, and 6 months of age; may be given as early as 6 weeks of age and repeated every 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fourth dose: Given at ~15 to 20 months of age, but at least 6 months after third dose. The fourth dose may be given as early as 12 months of age.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fifth dose: Given at 4 to 6 years of age, prior to starting school or kindergarten; if the fourth dose is given at &ge;4 years of age, the fifth dose may be omitted</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For children who start primary immunization series &ge;4 months of age, refer to current ACIP &quot;Catch-up Immunization Schedule&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization: ACIP recommendations:</b> <b>Note:</b> Tdap can be administered regardless of the interval between the last tetanus or diphtheria toxoid containing vaccine. Tdap is currently recommended for a single dose only (CDC/ACIP 60[1] 2011), except pregnant females who should receive a Tdap dose during each pregnancy (preferably during the early part of 27 and 36 weeks&rsquo; gestation) (CDC/ACIP 62[7] 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;10 years and Adolescents to 18 years: IM: 0.5 mL per dose. Tdap should be given as a single booster dose at age 11 or 12 years in adolescents who have completed a childhood DTaP vaccination series, followed by booster doses of Td every 10 years. Adolescents who have not received Tdap at age 11 or 12 should receive a single dose of Tdap in place of a single Td booster dose (ACIP [Robinson 2017]; CDC [Broder 2006]; CDC/ACIP 60[1] 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization: Manufacturer's labeling:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years and Adolescents (Adacel, Boostrix): 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Wound management:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062959\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Booster Immunization:</b> IM: Adults &ge;65 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ACIP recommendations: Refer to adult dosing. In adults &ge;65 years Boostrix should be used if feasible; however, ACIP has concluded that either Tdap vaccine (Boostrix or Adacel) may be used (CDC/ACIP 61[25] 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: Boostrix: 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Wound Management:</b> IM: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28604167\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28604168\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161248\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [Tdap, booster formulation]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adacel: Diphtheria 2 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 2.5 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [contains aluminum; may contain natural rubber/natural latex in prefilled syringe] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Boostrix: Diphtheria 2.5 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 8 mcg, filamentous hemagglutinin 8 mcg, pertactin 2.5 mcg] per 0.5 mL (0.5 mL) [contains aluminum and polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [DTaP, active immunization formulation]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daptacel: Diphtheria 15 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 10 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix: Diphtheria 25 Lf units, tetanus 10 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum and polysorbate 80; prefilled syringes contain natural rubber/natural latex]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734108\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DTaP: In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html&amp;token=AAHYoDAb5A/YSr8VQiRYJsJa+xtSDgw+x9go1noRHegLn8TcWE84hJbdbbfdAqbiCOgxMY984FLBv0YiMFNR1w==&amp;TOPIC_ID=9373\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html</a>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tdap: In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.html&amp;token=AAHYoDAb5A/YSr8VQiRYJsJa+xtSDgw+x9go1noRHegLn8TcWE84hJbdbbfdAqbifik+WgfcvRXQHsixPvGgsQ==&amp;TOPIC_ID=9373\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161251\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Administer IM. Shake suspension well. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adacel, Boostrix: Administer only IM in deltoid muscle of upper arm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daptacel, Infanrix: Administer only IM in anterolateral aspect of thigh or deltoid muscle of upper arm.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161249\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diphtheria, tetanus, and pertussis disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daptacel, Infanrix (DTaP): Active immunization against diphtheria, tetanus, and pertussis from age 6 weeks through 6 years of age (prior to seventh birthday)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adacel, Boostrix (Tdap): Active booster immunization against diphtheria, tetanus, and pertussis in persons 10 years and older (Boostrix) or persons 10 to 64 years of age (Adacel)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants and Children 6 weeks to &lt;7 years (DTaP):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; For primary immunization against diphtheria, tetanus and pertussis (ACIP 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients who are wounded in bombings or similar mass casualty events and who have penetrating injuries or nonintact skin exposure, and have an uncertain vaccination history should receive a tetanus booster with DTaP (if no contraindications exist) (CDC [Chapman 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 7 to 10 years (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children who did not complete a full primary DTaP series should receive a single dose of Tdap (if no contraindications exist) (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children never vaccinated against diphtheria, tetanus, or pertussis, or whose vaccination status is not known should receive a series of three vaccinations containing tetanus and diphtheria toxoids and the first dose should be with Tdap (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents 11 to 18 years (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; A single dose of Tdap as a booster dose in adolescents who have completed the recommended childhood DTaP vaccination series (preferred age of administration is 11 to 12 years) (CDC/ACIP 60[1] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents &ge;11 years and adults (Tdap):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons wounded in bombings or similar mass casualty events and who cannot confirm receipt of a tetanus booster within the previous 5 years and who have penetrating injuries or nonintact skin exposure should receive a single dose of Tdap (CDC/ACIP 61[25] 2012; CDC [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregnant patients: (Tdap): Pregnant females should receive a single dose with each pregnancy, preferably during the early part of 27 to 36 weeks gestation (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults &ge;19 years (including adults &ge;65 years) (Tdap): A single dose of Tdap should be given to all patients who have not previously received Tdap or for whom their vaccine status is unknown. Following administration of Tdap, Td vaccine should be used for routine boosters (ACIP [Kim 2017]). The following patients, who have not yet received Tdap or for whom vaccine status is not known, should receive a single dose of Tdap as soon as feasible:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Close contacts of children &lt;12 months of age; Tdap should ideally be administered at least 2 weeks prior to beginning close contact (CDC/ACIP 60[41] 2011; CDC/ACIP [Kretsinger 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Health care providers with direct patient contact (CDC/ACIP [Kretsinger 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Tdap is currently recommended for a single dose only (all age groups) (CDC/ACIP 60[1] 2011; CDC/ACIP 61[25] 2012), except pregnant females (CDC/ACIP 62[7] 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2671735\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Adacel (Tdap) may be confused with Daptacel (DTaP)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tdap (Adacel, Boostrix) may be confused with DTaP (Daptacel, Infanrix, Tripedia)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Carefully review product labeling to prevent inadvertent administration of Tdap when DTaP is indicated. Tdap contains lower amounts of diphtheria toxoid and some pertussis antigens than DTaP.</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">DTaP is indicated for use in persons &le;6 years of age</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Tdap is indicated for use in children &ge;10 years of age. If needed, Tdap can be used for children 7 to 10 years (CDC/ACIP, 60[1] 2011)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Guidelines are available in case of inadvertent administration of these products; refer to ACIP recommendations, February 2006 available at <a target=\"_blank\" href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsbCRzI0l2D55/Qbax/5ovYd2Ipr9o4pHSFJtEeeVfugoYvFaLp3hNs8ejrHqGht//Q==&amp;TOPIC_ID=9373\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm</a></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTaP: Diphtheria and tetanus toxoids and acellular pertussis vaccine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTP: Diphtheria and tetanus toxoids and pertussis vaccine (unspecified pertussis antigens)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTwP: Diphtheria and tetanus toxoids and whole-cell pertussis vaccine (no longer available on US market)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tdap: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161242\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the US  Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=9373\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b>  In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Daptacel, Infanrix</b> (incidence of erythema, swelling, and fever increases with successive doses): Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness, irritability, lethargy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Decreased appetite, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Erythema at injection site, local pain, localized edema, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Crying (prolonged or persistent), fever, fussiness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Postmarketing and/or case reports: Anaphylaxis, angioedema, apnea, brain disease, bronchitis, cellulitis, cough, cyanosis, diarrhea, erythema, fatigue, headache, hypersensitivity reaction, hypotonia, hypotonic/hyporesponsive episode, immune thrombocytopenia, infantile spasm, injection site reaction (abscess, cellulitis, induration, mass, nodule, rash), lymphadenopathy, nausea, otalgia, peripheral edema, pruritus, respiratory tract infection, screaming, seizure, skin rash, sudden infant death syndrome, thrombocytopenia, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Adacel, Boostrix: Note: Ranges presented, actual percent varies by product and age group</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (adolescents 43% to 44%; adults 30% to 34%; older adults 12%), fatigue (adolescents 37%; adults 28%; older adults 13%), chills (8% to 15%; severe &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased arm circumference (children 30% to 38%; adolescents 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal symptoms (includes abdominal pain, diarrhea, nausea, and/or vomiting; adolescents 26%; adults 16%; older adults 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site (adolescents 62% to 80%; adults 61% to 66%; older adults 22%), erythema at injection site (21% to 48%; adults 21% to 25%; older adults 11%), swelling at injection site (adolescents 21% to 39%; adults 18% to 21%; older adults 8%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (22% to 30%; severe: 1%), arthralgia (9% to 11%; severe: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&ge;38&deg;C [&ge;100.4&deg;F]: adolescents 5% to 14%; adults 1% to 6%; older adults 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Adacel, Boostrix</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylaxis, back pain, diabetes mellitus, encephalitis, facial paralysis, Guillain-Barre syndrome, hypersensitivity reaction, hypoesthesia, IgA vasculitis, injection site reaction (bruising, induration, inflammation, mass, nodule, pruritus, sterile abscess, warmth), lymphadenitis, lymphadenopathy, myalgia, myocarditis, myositis, nerve compression, paresthesia, peripheral edema (extensive), pruritus, seizure, syncope, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">\n      <b>Daptacel, Infanrix</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylaxis, angioedema, apnea, back pain, brain disease, bronchitis, cellulitis, cough, cyanosis, diabetes mellitus, diarrhea, encephalitis, erythema, facial paralysis, fatigue, Guillain-Barre syndrome, headache, hypersensitivity reaction, hypoesthesia, hypotonia, IgA vasculitis, immune thrombocytopenia, infantile spasm, injection site reaction (abscess, bruising, cellulitis, induration, inflammation, mass, nodule, pruritus, sterile abscess, rash, warmth), lymphadenopathy, nausea, otalgia, peripheral edema, pruritus, respiratory tract infection, screaming, seizure, skin rash, sudden infant death syndrome, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161253\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to diphtheria, tetanus toxoids, pertussis, or any component of the formulation; progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy or progressive epilepsy (postpone until condition stabilized) (Infanrix only); encephalopathy occurring within 7 days of administration and not attributable to another cause; administration to children and adults &ge;7 years (Daptacel only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161240\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arthus-type hypersensitivity: Patients with a history of severe local reaction (Arthus-type) following a previous diphtheria toxoid or tetanus toxoid-containing vaccine dose should not be given further routine or emergency doses of Td more frequently than every 10 years, even if using for wound management with wounds that are not clean or minor; these patients generally have high serum antitoxin levels (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reactions from previous dose: Carefully consider use in patients with history of any of the following effects from previous administration of any pertussis-containing vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid-containing vaccine (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic disorders: Use with caution in patients with progressive neurologic disease including infantile spasms, uncontrolled seizure, or a progressive encephalopathy, or conditions predisposing to seizures; ACIP guidelines recommend deferring immunization until health status can be assessed and condition stabilized (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]). Administration of Menactra (meningococcal MenACWY-D conjugate vaccine) one month after Daptacel has been shown to have reduced meningococcal antibody responses in children 4 to 6 years; these vaccines should be administered simultaneously or Menactra should be administered prior to Daptacel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids); may have a reduced response to vaccination. May be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has been reported following IM vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adacel: Formulated with the same antigens found in Daptacel, but with reduced quantities of tetanus and pertussis. Use in the primary immunization series or to complete the primary series has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Boostrix: Formulated with the same antigens found in Infanrix, but in reduced quantities. Use in the primary immunization series or to complete the primary series has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Per the manufacturer, antipyretic prophylaxis may be considered for patients at high risk for seizures. However, antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299219\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161243\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9373&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine: Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine may diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine. More specifically, prior administration of the diphtheria and tetanus toxoids, and acellular pertussis vaccine may diminish antibody response to the meningococcal (groups A / C / Y / and W-135) diphtheria conjugate vaccine in some patients.  Management: Administer the meningococcal (groups A / C / Y and W-135) diphtheria conjugate vaccine (Menactra brand) before or concurrently with the diphtheria and tetanus toxoids, and acellular pertussis vaccine (Daptacel brand) in children 4 to 6 years of age.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine: May diminish the therapeutic effect of Tetanus Toxoids Vaccines. Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161245\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161256\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted with all products; when conducted, adverse effects to the fetus were not observed in developmental toxicity studies. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). Daptacel and Infanrix are not recommended for use in a pregnant female or any patient &ge;7 years of age. Using data collected from 2005-2010 VAERS, there were not any patterns of adverse maternal, fetal, or neonatal outcomes identified following maternal use of the Tdap vaccine (Zheteyeva 2012). Additional VAERS data collected between 2011 and 2015 (after the current recommendations for use in pregnancy were in effect), also did not observe any new or unexpected maternal or newborn adverse events following maternal vaccination (Moro 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">All pregnant females should receive a single dose of Tdap during each pregnancy, regardless of previous vaccination status, preferably during the early part of 27 of 36 weeks gestation. Alternately, administration of Tdap can be given immediately postpartum to all females who have not previously been vaccinated with Tdap in order to protect the mother and infant from pertussis (ACIP [Kroger 2017]; CDC/ACIP 62[7] 2013). In case of an ongoing local pertussis epidemic, pregnant females should be vaccinated with Tdap for their own protection as is recommended for nonpregnant females, regardless of fetal gestational age. In addition, if a tetanus toxoid-containing vaccine is needed as standard care for wound management, Tdap may be given regardless of fetal gestational age if otherwise indicated. However, if Tdap is used prior to 27 to 36 weeks gestation in these instances, females should not receive more than 1 dose during the same pregnancy (ACOG 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy registries have been established for females who may become exposed to Boostrix (888-452-9622) or Adacel (800-822-2463) while pregnant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4043189\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if this vaccine is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer recommends that caution be used if administered to a breastfeeding female. Breastfeeding is not a contraindication to vaccine administration. Females who have not previously had a dose of Tdap should receive a dose postpartum to help prevent pertussis in infants &lt;12 months of age (CDC/ACIP 62[7] 2013). Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6839180\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for syncope for 15 minutes following administration ( ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161239\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunity to diphtheria, tetanus, and pertussis by inducing production of specific antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323115\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Adacel Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-2-15.5 lf-mcg/0.5 (0.5 mL): $52.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Boostrix Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-2.5-18.5 (0.5 mL): $47.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Daptacel Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15-23-5 lf-mcg/0.5 (0.5 mL): $35.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Infanrix Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-58-10 (0.5 mL): $28.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161257\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adacel (AU, HR, MT, PH, PL, RO, SG, VN);</li>\n      <li>Adsorbed DT COQ (HK, TW);</li>\n      <li>Anatoxal Di Te Per Berna (PE);</li>\n      <li>Boostagen (TH);</li>\n      <li>Boostrix (AE, AT, AU, CO, CY, CZ, DE, ES, FI, HK, IE, IL, KW, LB, LK, LT, LU, MX, NZ, PH, PL, SA, SG);</li>\n      <li>Boostrix-IPV (GB);</li>\n      <li>Bustryks (UA);</li>\n      <li>D.T. COQ (MY);</li>\n      <li>Dif per tet all (MY, PH, PK);</li>\n      <li>DiTePer Anatoxal Berna Vaccine (HK, MY, PH);</li>\n      <li>DPT (TW);</li>\n      <li>Infanrix (AE, AT, BB, BE, BG, BM, BS, BZ, GY, HR, IT, JM, KW, LB, MX, NL, PL, QA, RO, SA, SE, SR, TT, TW);</li>\n      <li>P.D.T. Vax Purified (KR);</li>\n      <li>TRIAcelluvax (DE);</li>\n      <li>Tribik (JP);</li>\n      <li>Tripacel (AU, TH, TW);</li>\n      <li>Tripavac (PH);</li>\n      <li>Tripvac (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, Immunization and Emerging Infections Expert Work Group. Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. <i>Obstet Gynecol</i>. 2017;130(3):e153-e157. doi: 10.1097/AOG.0000000000002301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/28832489/pubmed\" target=\"_blank\" id=\"28832489\">28832489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broder KR, Cortese MM, Iskander JK, et al; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-3):1-34<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/16557217/pubmed\" target=\"_blank\" id=\"16557217\">16557217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(1):13-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/21228763/pubmed\" target=\"_blank\" id=\"21228763\">21228763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older&mdash;Advisory Committee on Immunization Practices (ACIP), 2012 [published correction appears in <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(27):515]. MMWR Morb Mortal Wkly Rep. 2012;61(25):468-470. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6125a4.htm?s_cid=mm6125a4_e\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6125a4.htm?s_cid=mm6125a4_e</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/22739778/pubmed\" target=\"_blank\" id=\"22739778\">22739778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women&mdash;Advisory Committee on Immunization Practices (ACIP), 2012. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(7):131-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/23425962/pubmed\" target=\"_blank\" id=\"23425962\">23425962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact With an Infant Aged &lt;12 Months --- Advisory Committee on Immunization Practices (ACIP), 2011&rdquo;, <i>MMWR Morb Mortal Wkly Rep</i>, 2011, 60(41):1424-26.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman LE, Sullivent EE, Grohskopf LA, et al; Centers for Disease Control and Prevention (CDC). Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events&mdash;United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). <i>MMWR Recomm Rep</i>. 2008;57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/21293327/pubmed\" target=\"_blank\" id=\"21293327\">21293327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daptacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; received September 23, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infanrix (diphtheria and tetanus toxoids, acellular pertussis vaccine, adsorbed) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kretsinger K, Broder K, Cortese MM, et al; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. <i>MMWR Recomm Rep</i>. 2006;55(RR-17):1-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/17167397/pubmed\" target=\"_blank\" id=\"17167397\">17167397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moro PL, Cragan J, Tepper N, et al. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015. <i>Vaccine</i>. 2016;34(20):2349-2353. doi: 10.1016/j.vaccine.2016.03.049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/27013434/pubmed\" target=\"_blank\" id=\"27013434\">27013434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pichichero ME, Rennels MB, Edwards KM, et al, &quot;Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and Adults,&quot; <i>JAMA</i>, 2005, 293:3003-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/15933223/pubmed\" target=\"_blank\" id=\"15933223\">15933223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28182607\"></a>Robinson CL; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for children and adolescents aged 18 years or younger&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). <i> MMWR Recomm Rep</i>. 2000;49(RR-13):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/11106289/pubmed\" target=\"_blank\" id=\"11106289\">11106289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheteyeva YA, Moro PL, Tepper NK, et al, &quot;Adverse Event Reports After Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines in Pregnant Women,&quot; <i>Am J Obstet Gynecol</i>, 2012, 207(1):59.e1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information/abstract-text/22727350/pubmed\" target=\"_blank\" id=\"22727350\">22727350</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9373 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F161261\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F161262\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F161272\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F161265\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F161268\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062959\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28604167\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28604168\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F161248\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F161236\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734108\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F161251\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F161249\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2671735\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F161242\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F161253\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F161240\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299219\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F161243\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F161245\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F161256\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4043189\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6839180\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F161239\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323115\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F161257\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9373|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-patient-drug-information\" class=\"drug drug_patient\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}